Cryopyrin-associated periodic syndromes are categorized as a spectrum of three autoinflammatory diseases, namely familial cold auto-inflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurological cutaneous articular syndrome. All are caused by mutations in the NLRP3 gene coding for cryopyrin and result in active interleukin-1 release: their rarity and shared clinical indicators involving skin, joints, central nervous system and eyes often mean that correct diagnosis is delayed. Onset occurs early in childhood, and life-long therapy with interleukin-1 blocking agents usually leads to tangible clinical remission and inflammatory marker normalization in a large number of patients, justifying the need to facilitate early diagnosis and thus avoid irreversible negative consequences for tissues and organs.

Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes / L. Cantarini, O. Lucherini, B. Frediani, M. Brizi, B. Bartolomei, R. Cimaz, M. Galeazzi, D. Rigante. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - 24:4(2011), pp. 827-836.

Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes

R. Cimaz;
2011

Abstract

Cryopyrin-associated periodic syndromes are categorized as a spectrum of three autoinflammatory diseases, namely familial cold auto-inflammatory syndrome, Muckle-Wells syndrome and chronic infantile neurological cutaneous articular syndrome. All are caused by mutations in the NLRP3 gene coding for cryopyrin and result in active interleukin-1 release: their rarity and shared clinical indicators involving skin, joints, central nervous system and eyes often mean that correct diagnosis is delayed. Onset occurs early in childhood, and life-long therapy with interleukin-1 blocking agents usually leads to tangible clinical remission and inflammatory marker normalization in a large number of patients, justifying the need to facilitate early diagnosis and thus avoid irreversible negative consequences for tissues and organs.
Anti-Inflammatory Agents; therapeutic use; Carrier Proteins; genetics; Cryopyrin-Associated Periodic Syndromes; diagnosis/drug therapy/genetics/immunology; Genetic Predisposition to Disease; Humans; Inflammation Mediators; metabolism; Interleukin-1; antagonists /&/ inhibitors/metabolism; Mutation
Settore MED/16 - Reumatologia
2011
Article (author)
File in questo prodotto:
File Dimensione Formato  
039463201102400402.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 8.53 MB
Formato Adobe PDF
8.53 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/666227
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 60
  • ???jsp.display-item.citation.isi??? 58
social impact